Skip to main content
logo
Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.440
-0.030 (-1.21%)
At close: Mar 13, 2026, 4:00 PM EDT
2.519
+0.079 (3.22%)
After-hours: Mar 13, 2026, 7:59 PM EDT

Esperion Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
403.14332.31116.3375.4878.45
Revenue Growth (YoY)
21.31%185.66%54.14%-3.79%-65.53%
Cost of Revenue
129.2268.643.2726.9714.22
Gross Profit
273.91263.7173.0748.5164.23
Selling, General & Admin
165.79163.07142.52109.08184.99
Research & Development
47.8546.2486.11118.93105.98
Total Operating Expenses
213.64209.31228.63228.01290.96
Operating Income
60.2754.4-155.56-179.5-226.73
Interest Expense
-84.6-59.25-58.98-56.81-46.35
Other Non-Operating Income (Expense)
3.49-46.95.292.653.98
Total Non-Operating Income (Expense)
-81.11-106.15-53.69-54.16-42.38
Pretax Income
-20.84-51.75-209.25-233.66-269.11
Provision for Income Taxes
1.84----
Net Income
-22.68-51.75-209.25-233.66-269.11
Net Income to Common
-22.68-51.75-209.25-233.66-269.11
Shares Outstanding (Basic)
2081871036629
Shares Outstanding (Diluted)
2081871036629
Shares Change (YoY)
11.05%81.54%55.26%129.76%5.20%
EPS (Basic)
-0.11-0.28-2.03-3.52-9.31
EPS (Diluted)
-0.11-0.28-2.03-3.52-9.31
Free Cash Flow
-13.09-23.97-135.49-174.83-263.81
Free Cash Flow Per Share
-0.06-0.13-1.31-2.63-9.13
Gross Margin
67.95%79.36%62.81%64.27%81.88%
Operating Margin
14.95%16.37%-133.72%-237.83%-289.02%
Profit Margin
-5.63%-15.57%-179.87%-309.58%-343.04%
FCF Margin
-3.25%-7.21%-116.46%-231.64%-336.29%
EBITDA
60.3854.47-155.4-179-226.12
EBITDA Margin
14.98%16.39%-133.58%-237.17%-288.24%
EBIT
60.2754.4-155.56-179.5-226.73
EBIT Margin
14.95%16.37%-133.72%-237.83%-289.02%
Effective Tax Rate
-8.83%0.00%0.00%0.00%0.00%
Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q